West Pharmaceutical Posts 31.74 Forward P/E, Earns D Value Grade
West Pharmaceutical Services reports a forward P/E of 31.74, PEG ratio of 3.32 and P/B ratio of 5.52, earning a D grade in the Style Scores Value category. Despite holding a Zacks Rank 2, these metrics suggest it is less attractively valued than peers for value investors.
1. Valuation Metrics for West Pharmaceutical
West reports a forward P/E ratio of 31.74, a PEG ratio of 3.32 and a P/B ratio of 5.52, positioning it at the lower end of value investor criteria and earning a D grade in the Style Scores Value category.
2. Zacks Rank Reflects Earnings Revisions
The company holds a Zacks Rank #2 based on recent positive earnings estimate revisions, indicating an improving outlook, but its comparatively high valuation metrics may limit upside potential relative to peers.
Related News
INTC
Nvidia’s $91B AI Forecast, $80B Buyback Ramps Up Pressure on Intel
INTC•
AVGO
Nvidia Predicts $91B Q3 Sales, Boosts Dividend and $80B Buyback; Broadcom Poised for AI Inference Growth
AVGO•
INTU
Intuit Beats Q3 Estimates, Cuts 17% Workforce and Raises Guidance
INTU•
APURU
Aperture AC Prices $90 Million IPO of 9 Million Units at $10
APURU•
TGT
Target CEO Highlights Under-$10 Toy Sales Surge Despite High Costs
TGT•
Sources
FF